FAMPRIDINE-RELATED ATRIAL FIBRILLATION: TWO CASE REPORTS

B. TAUSTE HERNÁNDEZ¹, E. TEJEDOR TEJADA¹, I. ANDRADE ANDRADE², I. ALF EREZ GARCÍA¹.
¹HOSPITAL TORRECÁRDENAS. PHARMACY, ALMERÍA, SPAIN.
²HOSPITAL TORRECÁRDENAS, NEUROLOGY UNIT, ALMERÍA, SPAIN.

BACKGROUND AND IMPORTANCE

Fampridine (4-aminopyridine) is a drug whose indication is to improve gait in adult patients with Multiple Sclerosis with walking disability.

It is important to describe adverse effects that occur in certain patients in order to prevent them in the future.

AIM AND OBJECTIVES

To describe two cases of atrial fibrillation found in patients who were treated with fampridine and its possible relationship with that.

MATERIALS AND METHODS

- 2 patients (68 and 74 years old)
- Patology: Progressive Secondary Multiple Sclerosis
- Comorbidities: Arterial Hypertension
- Treatment: Fampridine 10 mg/12h
- Both presented arrhythmic cardiorespiratory auscultation and generalized weakness
- Constants measured: SABP, DBP, Ta, SaO, HR
- Reaction causality evaluated with Naranjo’s algorithm

RESULTS

<table>
<thead>
<tr>
<th></th>
<th>SABP (mmHg)</th>
<th>DBP (mmHg)</th>
<th>Ta (ºC)</th>
<th>SaO (%)</th>
<th>HR (bpm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AVERAGE</td>
<td>140</td>
<td>85</td>
<td>36</td>
<td>95</td>
<td>105</td>
</tr>
</tbody>
</table>

- Electrocardiogram: no signs of ischemia and/or blockages in any of the cases.
- Hemogram: normalized for age.
- Biochemistry: not altered.
- Oral anticoagulants (acenocumarol) were prescribed and digoxine (0,5 mg/day) in one case.
- Fampridine was suspended.
- Naranjo’s algorithm: "probability" (score of 5)
- Regional pharmacovigilance centre was notified by Yellow Card.

CONCLUSION AND RELEVANCE

- Fampridine data sheet does not describes atrial fibrillation.
- We consider important to make a special monitoring of hypertension and heart rate in patients in treatment with Fampridine.

References and/or acknowledgements